Literature DB >> 28393718

Comorbidities and their impact on chronic obstructive pulmonary disease.

Neşe Dursunoğlu, Nurdan Köktürk1, Ayşe Baha, Ahmet Kaya Bilge, Şermin Börekçi, Fatma Çiftçi, Makbule Gezmen Karadağ, Ebru Çalık Kütükçü, Ayşın Noyan, Mehmet Polatlı, Zeynep Pınar Önen, Sevinç Sarınç, Sema Umut, Esra Uzaslan, Ayşe Kubat Üzüm, Öznur Akkoca Yıldız.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a complex disease that is associated with devastating outcomes resulting from lung involvement and several comorbidities. Comorbidities could impact on symptomology, quality of life, the complications, the management, economic burden and the mortality of the disease. The importance of comorbidities originates from their impact on the outcome of COPD. The most frequent comorbidities in COPD are cardiovascular, endocrinological, musculoskeletal, phycological disorders and lung cancer. Almost 50% of the COPD patients have 3 or more comorbidities. The recent Global Initiative of Obstructive Lung Disease (GOLD) Guideline suggested proactive search and the treatment of the comorbidities. However, there is no certain evidence demonstrating that active treatment of comorbidities improve the outcomes of COPD. However, it is well known that several comorbidities such as cardiovascular disease and lung cancer have greater impact on mortality caused by COPD. Several studies have shown that Charlson Comorbidity index or more recenty COPD Specific Comorbidity Index (COTE) has been found to be related with mortality of COPD. This concise review intended to summarize the most frequent comorbidities in association with their impact on COPD.

Entities:  

Mesh:

Year:  2016        PMID: 28393718

Source DB:  PubMed          Journal:  Tuberk Toraks        ISSN: 0494-1373


  6 in total

1.  The View of the Turkish Thoracic Society on the Report of the GOLD 2017 Global Strategy for the Diagnosis, Management, and Prevention of COPD.

Authors:  Nurdan Köktürk; Alev Gürgün; Elif Şen; Ali Kocabaş; Mehmet Polatlı; Sibel Atış Naycı; Lütfi Çöplü; Emel Tellioğlu; Funda Elmas; Ertürk Erdinç
Journal:  Turk Thorac J       Date:  2017-04-01

2.  Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands.

Authors:  Candan Kendir; Marjan van den Akker; Rein Vos; Job Metsemakers
Journal:  Eur J Gen Pract       Date:  2017-11-23       Impact factor: 1.904

Review 3.  Metabolic Disorders in Chronic Lung Diseases.

Authors:  Ourania Papaioannou; Theodoros Karampitsakos; Ilianna Barbayianni; Serafeim Chrysikos; Nikos Xylourgidis; Vasilis Tzilas; Demosthenes Bouros; Vasilis Aidinis; Argyrios Tzouvelekis
Journal:  Front Med (Lausanne)       Date:  2018-01-18

4.  Management of the COPD Patient with Comorbidities: An Experts Recommendation Document.

Authors:  Jesús Recio Iglesias; Jesús Díez-Manglano; Francisco López García; José Antonio Díaz Peromingo; Pere Almagro; José Manuel Varela Aguilar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-05-07

5.  Chronic Obstructive Pulmonary Disease and Off-Pump Coronary Surgery.

Authors:  Cengiz Ovalı; Aykut Şahin
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-05-18       Impact factor: 1.520

6.  Comorbidity phenotypes and risk of mortality in patients with ischaemic heart disease in the UK.

Authors:  Francesca Crowe; Dawit T Zemedikun; Kelvin Okoth; Nicola Jaime Adderley; Gavin Rudge; Mark Sheldon; Krishnarajah Nirantharakumar; Tom Marshall
Journal:  Heart       Date:  2020-04-09       Impact factor: 5.994

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.